CCL5 and myeloid sarcoma: Dhib-Jalbut et al. demonstrated that IFN-β treatment could reduce the expression of CCL5, CCL3, and CXCR3, which was associated with Th1 cells, increasing the expression of CCR4 which was often expressed by Th2 cells in MS patients [88, 89].